Ionizing radiation and the cell cycle: A review

Radiation Oncology Investigations

Volumn 4, Issue 4, 1996, Pages 147-158

  Rudoltz, Marc S ^a   Blank, Kenneth R ^a   Kao, Gary ^a   Muschel, Ruth J ^a   McKenna, W Gillies ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b 2 Donner ^*  (United States)

Author keywords

ataxia telangiectasia; cell cycle checkpoints; ionizing radiation

Indexed keywords

ANTINEOPLASTIC AGENT; CAFFEINE; CYCLIN DEPENDENT KINASE; HYDROXYUREA; METHYLXANTHINE; PENTOXIFYLLINE; PROTEIN P53; RADIOSENSITIZING AGENT; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR;

ANIMAL CELL; APOPTOSIS; ATAXIA TELANGIECTASIA; CANCER; CANCER RADIOTHERAPY; CELL CYCLE; CELL CYCLE PHASE; CLINICAL PROTOCOL; DNA DAMAGE; DNA REPAIR; DNA REPLICATION; HELA CELL; HUMAN; HUMAN CELL; IONIZING RADIATION; MOLECULAR CLONING; NONHUMAN; PRIORITY JOURNAL; RADIOSENSITIVITY; REVIEW; TUMOR SUPPRESSOR GENE;

EID: 0029848186     PISSN: 10657541     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1520-6823(1996)4:4<147::AID-ROI1>3.0.CO;2-Y     Document Type: Review

References (125)

1. Howard A, Pelc SR: Synthesis of deoxyribonucleic acid in normal and irradiated cells and its relation to chromosome breakage. Heredity (Suppl) 6:261-273, 1953.
2. Terasima T, Tolmach LJ: Variations in several responses of Hela cells to X-irradiation during the division cycle. Biophys J 3:11-33, 1963.
3. Sinclair W, Morton R: Variations in X-ray response during the division cycle of partially synchronized Chinese hamster cells in culture. Nature 199:1158-1160, 1963.
4. Timson J: Hydroxyurea. Mutat Res 32:115-132, 1975.
5. McGinn CJ, Kinsella TK: The clinical rationale for S-phase radiosensitization in human tumors. Curr Probl Cancer 17:273-321, 1993.
6. Horiot JC, Le Fur R, N'Guyen T, Chenal C, Schraub S, Alfonsi S, Gardani G, van den Boegaert W, Danczak S, Bolla M, van Glabbeke M, De Pauw M: Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: Final analysis of a randomized trial of the EORTC cooperative group of radiotherapy. Radiother Oncol 25:231-241, 1992.
7. Corvo R, Giaretti W, Sanguineti G, et al.: In vivo cell kinetics in head and neck squamous cell carcinomas predicts local control and helps guide radiotherapy regimen. J Clin Oncol 13:1843-1850, 1995.
8. pot in cancer of the uterine cervix: Correlation between two laboratories and preliminary clinical results. Int J Radiat Oncol Biol Phys 32:1319-1329, 1995.
9. Murray AW: Creative blocks: Cell-cycle checkpoints and feedback controls. Nature 359:599-604, 1992.
10. Maity A, McKenna WG, Muschel RJ: The molecular basis for cell cycle delays following ionizing radiation: A review. Radiother Oncol 31:1-13, 1994.
11. Hartwell LH, Weinert TA: Checkpoints: Controls that ensure the order of cell cycle events. Science 246:629-634, 1989.
12. Yamada M, Puck TT: Action of radiation on mammalian cells. IV. Reversible mitotic lag in the S3 Hela cell produced by low doses of X-rays. Proc Natl Acad Sci USA 47:1181-1191, 1961.
13. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW: Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51:6304-6311, 1991.
14. Painter RB, Young BR: X-ray-induced inhibition of DNA synthesis in Chinese hamster ovary, human HeLa, and mouse L cells. Radiat Res 64:648-656, 1975.
15. Hartwell L, Kastan M: Cell cycle control and cancer. Science 266:1821-1828, 1994.
16. Carr A: Radiation checkpoints in model systems. Int J Radiat Biol 66(Suppl 6):S133-139, 1994.
17. Savitsky K, Bar-Shira A, Gilad S, et al.: A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science 268:1749-1753, 1995.
18. Morgan DO: Principles of CDK regulation. Nature 374:131-134, 1995.
19. Reznitsky D, Gossen M, Bujard H, Reed S: Acceleration of the G1/S phase transition by expression of cyclins D1 and E with an inducible system. Mol Cell Biol 14:1669-1679, 1994.
20. Ohtsubo M, Roberts JM: Cyclin-dependent regulation of G1 in mammalian fibroblasts. Science 259:1908-1912, 1993.
21. Pardee A: A restriction point for control of normal cell proliferation. Proc Natl Acad Sci USA 71:1286-1290, 1974.
22. Bartkova J, Lukas J, Strauss M, Bartek J: Cyclin D1 oncoprotein aberrantly accumulates in malignancies of diverse histogenesis. Oncogene 10:775-778, 1995.
23. Leach F, Elledge S, Sherr C, Willson J, Markowitz S, Kinzler K, Vogelstein B: Amplification of cyclin genes in colorectal carcinomas. Cancer Res 53:1986-1989, 1993.
24. INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 269:1281-1284, 1995.
25. Sicinski P, Donaher J, Parker S, Li T, Fazeli A, Gardner H, Haslam S, Bronson R, Elledge S, Weinberg R: Cyclin D1 provides a link between development and oncogenesis in the retina and breast. Cell 82:621-630, 1995.
26. Ewen M, Sluss H, Whitehouse L, Livingston D: TGF beta inhibition of Cdk4 synthesis is linked to cell cycle arrest. Cell 74:1009-1020, 1993.
27. Shiyanov P, Bagchi S, Adami G, Kokontis J, Hay N, Arroyo M, Morozov A, Raychaudhuri P: p21 disrupts the interactions between cdk2 and E2F. Mol Cell Biol 16:737-744, 1996.
28. Harper J, Adami G, Wei N, Keyomarsi K, Elledge S: The p21 cdk interacting protein cip1 is a potent inhibitor of G1 cyclin dependent kinases. Cell 75:805-816, 1993.
29. El-Deiry W, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer EW, Kinzler KW, Vogelstein B: WAF1, a potential mediator of p53 tumor suppression. Cell 75:817-825, 1993.
30. Hirami T, Koeffler P: Role of cyclin dependent kinase inhibitors in the development of cancer. Blood 86:841-854, 1995.
31. Xiong Y, Hannon G, Zhang H, Casso D, Kobayashi R, Beach D: p21 is a universal inhibitor of cyclin kinases. Nature 366:701-704, 1993.
32. El-Deiry WS, Kern SE, Pietenpol JA, Kinzler KW, Vogelstein B: Definition of a consensus binding site for p53. Nat Genet 1:45-49, 1992.
33. Gu Y, Turck CW, Morgan DO: Inhibition of CDK2 activity in vivo by an associated 20K regulatory sub-unit. Nature 366:707-710, 1993.
34. Deng C, Zhang P, Harper JW, Harper JW, Elledge SJ, Leder P: Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell 82:675-684, 1995.
35. Brugarolas J, Chandrasekaran C, Gordon JI, Beach D, Jacks T, Hannon GJ: Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature 377:552-557, 1995.
36. Nelson WG, Kastan MB: DNA strand breaks: The DNA template alterations that trigger p53-dependent DNA damage response pathways. Mol Cell Biol 14:1815-1823, 1994.
37. Lee J, Bernstein A: Apoptosis, cancer and the p53 tumour suppressor gene. Cancer Met Rev 14:149-161, 1995.
38. Kuerbitz SJ, Plunkett BS, Walsh WV, Kastan MB: Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci USA 89:7491-7495, 1992.
39. Li R, Waga S, Hannon GJ, Beach D, Stillman B: Differential effects of the p21 CDK inhibitor on PCNA-dependent DNA replication and repair. Nature 371:534-537, 1994.
40. Cip1. Science 375:159-161, 1995.
41. Smith ML, Chen I-T, Zhan Q, Bae I, Chen C-Y, Gilmer TM, Kastan MB, O'Connor PM, Fornace AJ Jr: Interaction of the p53-regulated protein gadd45 with proliferating cell nuclear antigen. Science 266:1376-1380, 1994.
42. Martin K, Trouche D, Hagemeier C, Sorenson T, La Thangue N, Kouzarides T: Stimulation of E2F/DP1 transcriptional activity by MDM2 oncoprotein. Nature 375:691-694, 1995.
43. Xiao Z, Chen J, Levine A, Modjtahedi N, Xing J, Sellers W, Livingston D: Interaction between the retinoblastoma protein and the oncoprotein MDM2. Nature 375:694-698, 1995.
44. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, Housman DE, Jacks T: p53 status and the efficacy of cancer therapy in vivo. Science 266:807-810, 1994.
45. Hollstein M, Sidransky D, Vogelstein B, Harris CC: p53 mutations in human cancers. Science 253:49-53, 1991.
46. Chang F, Syrjanen S, Syrjanen K: Implications of the p53 tumor-suppressor gene in clinical oncology. J Clin Oncol 13:1009-1022, 1995.
47. Fisher DE: Apoptosis in cancer therapy: Crossing the threshold. Cell 78:539-542, 1994.
48. Lee J, Bernstein A: p53 mutations increase resistance to ionizing radiation. Proc Natl Acad Sci USA 90:5742-5746, 1993.
49. Bristow RG, Jang A, Peacock J, Chung S, Benchimol S, Hill RP: Mutant p53 increases radioresistance in rat embryo fibroblasts simultaneously transfected with HPV16-E7 and/or activated H-ras. Oncogene 9:1527-1536, 1994.
50. McIlwrath AJ, Vasey PA, Ross GM, Brown R: Cell cycle arrests and radiosensitivity of human tumor cell lines: Dependence on wild-type p53 for radiosensitivity. Cancer Res 54:3718-3722, 1994.
51. O'Connor PM, Jackman J, Jondle D, Bhatia K, Magrath I, Kohn KW: Role of the p53 tumor suppressor gene in cell cycle arrest and radiosensitivity of Burkitt's lymphoma cell lines. Cancer Res 53:4776-4780, 1993.
52. Slichenmyer WJ, Nelson WG, Slebos RJ, Kastan MB: Loss of a p53-associated G1 checkpoint does not decrease cell survival following DNA damage. Cancer Res 53:4164-4168, 1993.
53. Guillouf C, Grana X, Selvakumaran M, De Luca A, Giordano A, Hoffman B, Liebermann DA: Dissection of the genetic programs of p53-mediated G1 growth arrest and apoptosis: Blocking p53-induced apoptosis unmasks G1 arrest. Blood 85:2691-2698, 1995.
54. Stephens LC, Ang KK, Schultheiss TE, Milas L, Meyn RE: Apoptosis in irradiated murine tumors. Radiat Res 127:308-316, 1991.
55. Story MD, Voehringer DW, Malone CG, Hobbs ML, Meyn RE: Radiation-induced apoptosis in sensitive and resistant cells isolated from a mouse lymphoma. Int J Radiat Biol 66:659-668, 1994.
56. Rudoltz MS, Kao G, Bernhard EJ, Bakanauskas VJ, Muschel RJ, McKenna WG: Unpublished data.
57. Yin DX, Schimke RT: Bcl-2 expression delays drug-induced apoptosis but does not increase clonogenic survival after drug treatment in HeLa cells. Cancer Res 55:4922-4928, 1995.
58. Munger K, Werness B, Dyson N, Phelps W, Harlow E, Howley P: Complex formation of human papillomavirus E7 proteins with the retinoblastoma tumor suppressor gene product. EMBO J 8:4099-4105, 1989.
59. Scheffner M, Werness B, Huibregtse J, Levine A, Howley P: The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63:1129-1136, 1990.
60. Hunter T, Pines J: Cyclins and cancer. II: Cyclin D and CDK inhibitors come of age. Cell 79:573-582, 1994.
61. Hussussian C, Struewing J, Goldstein A, Higgins P, Ally D, Sheahan M, Clark WJ, Tucker M, Dracopoli N: Germline p16 mutations in familial melanoma. Nat Genet 8:15-21, 1994.
62. Goldstein A, Fraser M, Struewing J, et al.: Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutations. N Engl J Med 333:970-974, 1995.
63. Liu Q, Van Y, McClure M, Nakagawa H, Fujimura F, Rustgi A: MTS-1 (CDKN2) tumor suppressor gene deletions are a frequent event in esophagus squamous cancer and pancreatic adenocarcinoma cell lines. Oncogene 10:619-622, 1995.
64. Clayman GL, el-Naggar AK, Roth JA, Zhang WW, Goepfert H, Taylor DL, Liu TJ: In vivo molecular therapy with p53 adenovirus for microscopic residual head and neck squamous carcinoma. Cancer Res 55:1-6, 1995.
65. Liu TJ, Zhang WW, Taylor DL, Roth JA, Goepfert H, Clayman GL: Growth suppression of human head and neck cancer cells by the introduction of a wild-type p53 gene via a recombinant adenovirus. Cancer Res 54:3662-3667, 1994.
66. Liu TJ, el-Naggar AK, McDonnell TJ, Steck KD, Wang M, Taylor DL, Clayman GL: Apoptosis induction mediated by wild-type p53 adenoviral gene transfer in squamous cell carcinoma of the head and neck. Cancer Res 55:3117-3122, 1995.
67. Su LN, Little JB: Prolonged cell cycle delay in radioresistant human cell lines transfected with acivated ras oncogene and/or simian virus 40 T-antigen. Radiat Res 133:73-79, 1993.
68. 2. Int J Radiat Biol 63:623-629, 1993.
69. Busse PM, Bose SK: The action of caffeine on X-irradiated HeLa cells. III. enhancement of X-ray induced killing during G2 arrest. Radiat Res 76:292-307, 1978.
70. Peterson L, Orren D, Bohr V: Gene-specific and strand-specific DNA repair in the G1 and G2 phases of the cell cycle. Mol Cell Biol 15:3731-3737, 1995.
71. Muschel RJ, Zhang HB, Iliakis G, McKenna WG: Effects of ionizing radiation on cyclin expression in HeLa cells. Radiat Res 132:153-157, 1992.
72. cdc2 regulation. Mol Cell Biol 13:1675-1685, 1993.
73. Clarke P: Cyclin-dependent kinases. CAK-handed kinase activation. Curr Biol 5:40-42, 1995.
74. cdc2/cyclin B complex in vitro by human CDC25 protein. Nature 351:242-245, 1991.
75. Dunphy WG, Kumagai A: The CDC25 protein contains an intrinsic phosphatase activity. Cell 67:189-196, 1991.
76. Hoffmann I, Clarke PR, Marcote MJ, Karsenti E, Draetta G: Phosphorylation and activation of human CDC25-C by cdc2 -cyclin B and its involvement in the self-amplification of MPF at mitosis. EMBO J 12:53-63, 1993.
77. cdc2-cyclin B complex by the human weel tyrosine kinase. Science 257:1955-1957, 1992.
78. cdc2 exclusively on Tyr15. EMBO J 12:75-85, 1993.
79. Enoch T, Nurse P: Mutation of fission yeast cell cycle control genes abolishes dependence of mitosis on DNA replication. Cell 60:665-673, 1990.
80. Rowley R, Hudson J, Young PG: The weel protein kinase is required for radiation-induced mitotic delay. Nature 356:353-355, 1992.
81. Enoch T, Carr AM, Nurse P: Fission yeast genes involved in coupling mitosis to completion of DNA replication. Genes Dev 6:2035-2046, 1992.
82. Sklar MD: The ras oncogenes increase the intrinsic resistance of NIH 3T3 cells to ionizing radiation. Science 239:645-647, 1988.
83. McKenna W, Weiss M, Bakanauskas V, Sandler H, Kelsten M, Biaglow J, Endlich B, Ling C, Muschel R: The role of the H-ras oncogene in radiation resistance and metastasis. Int J Radiat Oncol Biol Phys 18:849-860, 1990.
84. 2 delay in radiation-resistant cells obtained by transformation of primary rat embryo cells with the oncogenes v-myc and H-ras. Radiat Res 125:283-287, 1991.
85. Muschel R, Zhang H, Iliakis G, McKenna W: Cyclin B expression in HeLa cells during the G2 block induced by radiation. Cancer Res 51:5113-5117, 1991.
86. Muschel RJ, Zhang HB, McKenna WG: Differential effect of ionizing radiation on the expression of cyclin A and cyclin B in HeLa cells. Cancer Res 53:1128-1135, 1993.
87. Maity A, McKenna WG, Muschel RJ: Evidence for posttranscriptional regulation of cyclin B1 mRNA in the cell cycle and following irradiation in HeLa cells. EMBO J 14:603-609, 1995.
88. Metting N, Little J: Transient failure to dephosphorylate the cdc2-cyclin B1 complex accompanies radiation-induced G2 phase arrest in HeLa cells. Radiat Res 143:286-292, 1995.
89. Barth H, Hoffmann I, Kinzel V: Radiation with 1 Gy prevents the activation of the mitotic inducers mitosis-promoting factors (MPF) and cdc-25 in HeLa cells. Cancer Res 56:2268-2272, 1996.
90. Smeets M, Mooren E, Begg A: The effect of radiation on G2 blocks, cyclin B expression, and cdc2 expression in human squamous cell lines with different radiosensitivities. Radiother Oncol 33:217-227, 1994.
91. Weinert TA, Kiser GL, Hartwell LH: Mitotic checkpoint genes in budding yeast and the dependence of mitosis on DNA replication and repair. Genes Dev 8:652-665, 1994.
92. Bernhard EJ, Muschel RJ, Bakanauskas VJ, McKenna WG: Reducing the radiation-induced G2 delay causes HeLa cells to undergo apoptosis instead of mitotic death. Int J Radiat Biol 69:575-584, 1996.
93. Demarcq C, Bunch R, Creswell D, Eastman A: The role of cell cycle progression in cisplatin-induced apoptosis in Chinese hamster ovary cells. Cell Growth Differ 5:983-993, 1994.
94. Lock RB, Galperina OV, Feldhoff RC, Rhodes LJ: Concentration-dependent differences in the mechanisms by which caffeine potentiates etoposide cytotoxicity in HeLa cells. Cancer Res 54:4933-4939, 1994.
95. Cross SM, Sanchez CA, Morgan CA, Schimke MK, Ramel S, Idzerda RL, Raskind WH, Reid BJ: A p53-dependent mouse spindle checkpoint. Science 267:1353-1356, 1995.
96. Guillouf C, Rosselli F, Krishnaraju K, Moustacchi E, Hoffman B, Liebermann DA: p53 involvement in control of G2 exit of the cell cycle: Role in DNA damage-induced apoptosis. Oncogene 10:2263-2270, 1995.
97. Powell S, Defrank J, Connell P, Edgan M, Preffer F, Dombkowski D, Tang W, Friend S: Differential sensitivity of p53- and p53+ cells to caffeine-induced radiosensitization and override of G2 delay. Cancer Res 55:1643-1648, 1995.
98. 1 checkpoint-competent cells. Cancer Res 55:1639-1642, 1995.
99. Fan S, Smith M, Rivet D, Duba D, Zhan Q, Kohn K, Fornace A, O'Connor P: Disruption of p53 function sensitizes breast cancer MCF 7 cells to cisplatin and pentoxifylline. Cancer Res 55:1649-1654, 1995.
100. Lerner E, Qian Y, Blaskovich M, Fossum RD, Vogt A, Sun J, Cox A, Der C, Hamilton A, Sebti S: Ras CAAX peptidomimetic FTI-277 selectively blocks oncogenic ras signalling by inducing cytoplasmic accumulation of inactive ras-raf complexes. J Biol Chem 270:26802-26806, 1995.
101. Watanabe I: Radiation effects on DNA chain growth in mammalian cells. Radiat Res 58:541-556, 1974.
102. Makino F, Okada S: Effects of ionizing radiation on DNA replication in cultured mammalian cells. Radiat Res 62:37-51, 1975.
103. Painter RB, Young BR: Formation of nascent DNA molecules during inhibition of replicon initiation in mammalian cells. Biochim Biophys Acta 418:146-153, 1976.
104. Larner JM, Lee H, Hamlin JL: Radiation effects on DNA synthesis in a defined chromosomal replicon. Mol Cell Biol 14:1901-1908, 1994.
105. Wang Y, Cheong N, Iliakis G: Persistent inhibition of DNA synthesis in cells obtained by transformation of primary rat embryo fibroblasts with oncogenes H-ras and v-myc. Cancer Res 53:1993.
106. Wang Y, Iliakis G: Prolonged inhibition by X-rays of DNA synthesis in cells obtained by transformation of primary rat embryo fibroblasts with oncogenes H-ras and v-myc. Cancer Res 52:508-514, 1992.
107. Carr AM: DNA structure checkpoints in fission yeast. Semin Cell Biol 6:65-72, 1995.
108. Sedgwick R, Boder E: Ataxia-telangiectasia. Handb Clin Neural 16:347-423, 1991.
109. Peterson R, Funkhouser J, Tuck-Muller C, Gatti R: Cancer susceptibility in ataxia-telangiectasia. Leukemia 6(Suppl 1):8-13, 1992.
110. Thacker J: Cellular radiosensitivity in ataxia-telangiectasia. Int J Radiat Biol 66:S87-S96, 1994.
111. Murname JP: Cell cycle regulation in response to DNA damage in mammalian cells; a historical perspective. Cancer Met Rev 14:17-29, 1995.
112. Savitsky K, Sfez S, Tagle DA, Ziv Y, Sartiel A, Collins FS, Shiloh Y, Rotman G: The complete sequence of the coding region of the ATM gene reveals similarity to cell cycle regulators in different species. Hum Mol Genet 4:2025-2032, 1995.
113. Swift M, Reitnauer P, Morrell D, Chase C: Breast and other cancers in families with ataxia-telangiectasia. N Engl J Med 316:1289-1294, 1987.
114. Swift M, Morrell D, Massey R, Chase C: Incidence of cancer in 161 families affected by ataxia-telangiectasia. N Engl J Med 325:1831-1836, 1991.
115. Weeks D, Paterson M, Lange K, Andrais B, Davis R, Yoder F, Gatti R: Assessment of chronic gamma radiosensitivity as an in vitro assay for heterozygote identification of ataxia-telangiectasia. Radiat Res 128:90-99, 1991.
116. Meyn M: Ataxia-telangiectasia and cellular responses to DNA damage. Cancer Res 55:5991-6001, 1995.
117. Jorgenson TJ, Shiloh Y: The ATM gene and the radiobiology of ataxia-telangiectasia. Int J Radiat Biol 69:527-537, 1996.
118. Kastan MB, Zhan Q, El-Deiry WS, Carrier F, Jacks T, Walsh WV, Plundett BS, Vogenstein B, Fornace AJ Jr: A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 71:587-597, 1992.
119. Khanna K, Beamish H, Yan J, Hobson K, Williams R, Dunn I, Lavin M: Nature of G1/S cell cycle checkpoint defect in ataxia-telangiectasia. Oncogene 10:609-618, 1995.
120. Canman CE, Wolff AC, Chen C-Y, Fornace AJ Jr, Kastan MB: The p53-dependent G1 cell cycle checkpoint pathway and ataxia-telangiectasia. Cancer Res 54:5054-5058, 1994.
121. Beamish H, Lavin MF: Radiosensitivity in ataxia-telangiectasia: Anomalies in radiation-induced cell cycle delay. Int J Radiat Biol 65:175-184, 1989.
122. Walworth N, Bernards R: Rad-dependent response of the chk-1 encoded protein kinase at the DNA damage checkpoint. Science 271:353-356, 1996.
123. Sanchez Y, Desany B, Jones W, Liu Q, Wang B, Elledge S: Regulation of RAD53 by the ATM-like kinases MEC1 and TEL1 in yeast cell cycle checkpoint pathways. Science 271:357-360, 1996.
124. Bernhard EJ, Muschel RJ, Bakanauskas VJ, McKenna WG: Reducing the radiation-induced G2 delay causes HeLa cells to undergo apoptosis instead of mitotic death. Int J Radiat Biol 69:575-584, 1996.
125. Kim SH, Khil MS, Ryu S, Kim JH: Enhancement of radiation response of human carcinoma cells in culture by pentoxyfylline. Int J Radiat Oncol Biol Phys 25:61-65, 1992.